sabirnetug — Clinical data readout
Nov 2026
We are currently focused on advancing a targeted immunotherapy drug candidate, sabirnetug, in our Phase 2 ALTITUDE-AD clinical trial.Source filing
ABOS biotech catalysts & pipeline
ACUMEN PHARMACEUTICALS INC · Data as of 2026-10-27
Upcoming catalysts
ACU301 and ACU401 — IND submission
mid-2027
Based on these developments, an investigational new drug, or IND, application for the lead candidate is targeted for mid-2027.Source filing
ACU401 — IND submission
mid-2027
Lead candidate IND filing targeted for mid-2027Source filing
EBD candidate — IND submission
mid-2027
Lead clinical candidate IND filing targeted for mid-2027Source filing
EBD program lead clinical candidate — IND submission
mid-2027
Two candidates nominated for development in Acumen's Enhanced Brain Delivery™ (EBD™) program; lead clinical candidate IND filing for the EBD program targeted for mid-2027Source filing
Enhanced Brain Delivery (EBD) candidates — IND submission
mid-2027
Based on this data, an investigational new drug, or IND, application is targeted for mid-2027.Source filing
sabirnetug — Conference presentation
Nov 16–Nov 19
The conference will be held November 16-19, 2026, both in-person and online.Source filing